Healthy Clinical Trial
Official title:
A Phase I, Single-Blind Study to Determine the Safety, Tolerability and Pharmacodynamic Profiles of a Hepatitis B Antigen Combined With IMP321 Versus the Hepatitis B Antigen Alone and a Reference Vaccine in Healthy Young Male Volunteers
This is a single centre, three single administrations (Days 1, 29 and 57) at increasing doses of IMP321 (3, 10, 30 and 100 µg) in four cohorts of 12 subjects, single blind, randomized study.
In each cohort, 8 subjects will receive the hepatitis B antigen (10 µg) with IMP321 at one
dose, 2 subjects will receive the reference hepatitis B antigen (10 µg) alone with
physiological saline and 2 subjects will receive the commercial vaccine Engerix B® (20 µg).
Engerix B® will be administered intramuscularly. The other treatments will be administered
subcutaneously.
The four successive cohorts of volunteers will be:
Cohort A:
- 8 subjects treated by hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with
IMP321 (3 µg),
- 2 subjects treated by hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with
physiological saline,
- 2 subjects treated by the commercial hepatitis vaccine Engerix B® (20 µg HBsAg with
alum).
If the tolerability of this cohort is acceptable, the following cohort will be done.
Cohort B:
- 8 subjects treated by hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with
IMP321 (10 µg),
- 2 subjects treated by hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with
Physiological saline,
- 2 subjects treated by the commercial hepatitis vaccine Engerix B® (20 µg HBsAg with
alum).
If the tolerability of this cohort is acceptable, the following cohort will be done.
Cohort C:
- 8 subjects treated by hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with
IMP321 (30 µg),
- 2 subjects treated by hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with
physiological saline,
- 2 subjects treated by the commercial hepatitis vaccine Engerix B® (20 µg HBsAg with
alum).
If the tolerability of this cohort is acceptable, the following cohort will be done.
Cohort D:
- 8 subjects treated by hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with
IMP321 (100 µg),
- 2 subjects treated by hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with
physiological saline
- 2 subjects treated by the commercial hepatitis vaccine Engerix B® (20 µg HBsAg with
alum).
Blood samples will be collected on the morning of days 1, 29, 36, 57 and 85 for
pharmacodynamic evaluation.
Monitoring for the occurrence of adverse events (AE), changes in physical examination, vital
signs (blood pressure, pulse rate, respiration), electrocardiograms (ECG) and clinical
laboratory tests (biochemistry, haematology, urinalysis) will be performed before and after
each dose of the study drug to assess safety and tolerability.
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |